Tom Shea, Meitheal Pharmaceuticals CEO
Xentria and Meitheal ink licensing deal for rare lung disease treatment in North America
Xentria will license its experimental pulmonary sarcoidosis drug to Meitheal Pharmaceuticals in a deal worth up to $680 million.
Meitheal spun out Xentria in 2020 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.